https://www.selleckchem.com/pr....oducts/dorsomorphin-
Melasma severity and skin health were evaluated at 4 visits for each participant (baseline, weeks 4, 8, and 12, respectively). Severity of melasma scored by mMASI of the synbiotics group was 7.54±0.79, 7.36±0.80, 7.16±0.73, and 6.98±0.72 at baseline, weeks 4, 8, and 12, respectively, and 7.51±0.86, 7.52±0.88, 7.54±0.86, and 7.54±0.89 at baseline, weeks 4, 8, and 12, respectively, in the placebo group. Comparing between two groups at week 12, melasma score in the synbiotics supplement group was significantly lower than that in